• In late February 2026, NovoCure reported fourth-quarter 2025 revenue of US$174.35 million and a quarterly loss of US$24.5 million, alongside full-year 2025 revenue of US$655.35 million and a narrowed annual loss of US$136.23 million, while issuing 2026 net revenue guidance of US$675 million to US$705 million.
• Alongside these results, NovoCure secured U.S. FDA approval and began the commercial launch of Optune Pax for locally advanced pancreatic cancer, signaling a shift from a single-indication glioblastoma focus toward a broader multi-indication TTFields platform with new international and reimbursement opportunities.
• With Optune Pax now approved and launching in pancreatic cancer, we’ll examine how this changes NovoCure’s investment narrative and growth drivers.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.

NovoCure Investment Narrative Recap

To own NovoCure today, you need to believe TTFields can move from a niche glioblastoma franchise to a credible multi-indication oncology platform, while the company steadily closes its profitability gap. The key near term catalyst is the real world uptake and reimbursement of newly approved Optune Pax in pancreatic cancer; the biggest risk remains NovoCure’s persistent losses and uncertain path to sustained positive earnings. The latest results and guidance modestly de risk execution, but do not remove that concern.

Among recent announcements, the US FDA approval and commercial launch of Optune Pax for locally advanced pancreatic cancer stands out as most relevant. It turns pancreatic cancer from a clinical trial story into a commercial one, adding a second major indication alongside glioblastoma and creating new reimbursement and regulatory touchpoints in Europe and Japan. How quickly payors, oncologists, and patients embrace Optune Pax will heavily influence whether NovoCure’s 2026 revenue guidance proves achievable.

Yet beneath the promising Optune Pax launch, investors should be aware that NovoCure’s continued negative earnings and cash needs could still...

NovoCure's narrative projects $863.5 million revenue and $107.8 million earnings by 2028.

Uncover how NovoCure's forecasts yield a $25.21 fair value, a 84% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenues could reach about US$930 million by 2028 and earnings turn positive, while this latest Optune Pax approval and 2026 guidance may either support that faster adoption view or reinforce concerns about reimbursement and cost pressures, reminding you that well informed opinions on NovoCure’s upside and risks can differ sharply.

Explore 4 other fair value estimates on NovoCure - why the stock might be worth just $25.21!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your NovoCure research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free NovoCure research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NovoCure's overall financial health at a glance.

No Opportunity In NovoCure?

Our top stock finds are flying under the radar-for now. Get in early:

• Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 30 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.